Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis

Table 2

GH and IGF-I levels in MS patients, OND and HC subjects, according to sex and age.

GH (ng/mL)

IGF-I (ng/mL)

Tot

Sex

Age

Tot

Sex

Age

M

F

𝑃^§

<50 years

≥50 years

𝑃^§

M

F

𝑃^§

<50 years

≥50 years

𝑃^§

MS

0.87±1.32 (𝑛=64)

0.50±0.96 (𝑛=26)

1.15±1.48 (𝑛=37)

0.005

0.85±1.27 (𝑛=31)

0.89±1.38 (𝑛=33)

0.898

152.8±55.4 (𝑛=64)

145.3±49.0 (𝑛=26)

158.0±60.3 (𝑛=37)

0.434

171.7±61.2 (𝑛=31)

135.2±43.2 (𝑛=33)

0.005

OND

1.66±3.7 (𝑛=46)

0.49±0.74 (𝑛=20)

2.55±4.72 (𝑛=26)

0.002

1.39±2.53 (𝑛=24)

1.95±4.71 (𝑛=22)

0.509

162.3±77.9 (𝑛=46)

161.8±74.5 (𝑛=20)

162.7±81.8 (𝑛=26)

0.706

190.3±73.3 (𝑛=24)

131.8±72.4 (𝑛=22)

0.004

HC

1.69±3.35 (𝑛=62)

0.45±0.88 (𝑛=23)

2.42±4.00 (𝑛=39)

0.005

2.24±4.17 (𝑛=33)

1.06±1.94 (𝑛=29)

0.374

136.4±47.4 (𝑛=62)

141.1±45.7 (𝑛=23)

133.7±8.69 (𝑛=39)

0.512

147.5±43.5 (𝑛=33)

123.8±49.1 (𝑛=29)

0.012

𝑃^§§

0.858

0.910

0.545

0.783

0.840

0.160

0.606

0.140

0.061

0.362

𝑃^§ Mann-Whitney 𝑈-test was used to compare MS versus OND and MS versus HC; 𝑃^§§ Kruskal-Wallis test was employed. GH in MS female shows a trend for lower value than in OND and HC females. Values are expressed as means ± SD. MS: Multiple Sclerosis; OND: other neurological disease; HC: healthy controls; M: male; F: female.